Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial)

Fig. 2

Probability of having WHO Ordinal Scale < 6 in the study groups over time. A is showing Kaplan–Meier estimates of freedom from primary outcome after initiation of the study drugs (atorvastatin, aspirin, and both) in comparison to the standard of care (modified ITT analysis). B and C are showing Kaplan–Meier estimates of probability of freedom from primary outcome in combined atorvastatin (Group A and Group C) and combined aspirin (Group B and Group C) groups respectively in comparison to the standard of care (modified ITT analysis). CI confidence interval, HR hazard ratio, WHO World Health Organisation

Back to article page